Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5466)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Cammarota G, Ianiro G, Bibbò S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. Culture-guided treatment approach for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i18/5205.htm |
| Number | Citing Articles |
| 1 |
Nazlı Arslan, Özlem Yılmaz, Ebru Demiray-Gürbüz. Importance of antimicrobial susceptibility testing for the management of eradication in <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2017; 23(16): 2854-2869 doi: 10.3748/wjg.v23.i16.2854
|
| 2 |
Elham Tabesh, Farzad Yadmehr, Awat Feizi, Farzin Khorvash, Setayesh Sindarreh, Atousa Hakamifard. Sequential therapy versus quadruple therapy for Helicobacter pylori eradication: A prospective double‐blinded randomized controlled trial. Health Science Reports 2024; 7(1) doi: 10.1002/hsr2.1842
|
| 3 |
Ana Morilla Morilla, Marta E. Álvarez-Argüelles, Jose María Duque, Edisa Armesto, Henar Villar, Santiago Melón. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología 2019; 42(8): 476 doi: 10.1016/j.gastrohep.2019.05.002
|
| 4 |
Floriana Giorgio, Enzo Ierardi, Claudia Sorrentino, Mariabeatrice Principi, Michele Barone, Giuseppe Losurdo, Andrea Iannone, Antonio Giangaspero, Rosa Monno, Alfredo Di Leo. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. Scandinavian Journal of Gastroenterology 2016; 51(12): 1429 doi: 10.1080/00365521.2016.1216592
|
| 5 |
Yong Hwan Kwon, Seong Woo Jeon, Su Youn Nam, Hyun Suk Lee, Ji Hey Park. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single‐center prospective pilot study. Helicobacter 2019; 24(4) doi: 10.1111/hel.12585
|
| 6 |
Taweesak Tongtawee, Soraya Kaewpitoon, Natthawut Kaewpitoon, Chavaboon Dechsukhum, Wilairat Leeanansaksiri, Ryan A. Loyd, Likit Matrakool, Sukij Panpimanmas. Characteristics and Risk Factors ofHelicobacter pyloriAssociated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/9130602
|
| 7 |
Davide Giuseppe Ribaldone, Giorgio Saracco, Rinaldo Pellicano. Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication ofHelicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/4760378
|
| 8 |
Jorge Alfredo Morcillo-Muñoz, William Alberto Regino-Otero, Martín Alonso Gómez Zuleta. Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?. Revista Colombiana de Gastroenterología 2018; 33(4): 437 doi: 10.22516/25007440.314
|
| 9 |
David Y. Graham. Editorial – Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility‐Based Studies and Probiotics as Adjuvants. Helicobacter 2015; 20(5): 321 doi: 10.1111/hel.12244
|
| 10 |
Xinlu Ren, Yanyan Shi, Baojun Suo, Xingyu Yao, Haoping Lu, Cailing Li, Yuxin Zhang, Liya Zhou, Xueli Tian, Zhiqiang Song. Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta‐analysis. Helicobacter 2023; 28(3) doi: 10.1111/hel.12958
|
| 11 |
Eskandar Hajiani, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh, Ali Akbar Shayesteh. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 2018; 10(4): 242 doi: 10.15171/mejdd.2018.117
|
| 12 |
Luis Bujanda, Olga P. Nyssen, Dino Vaira, Ilaria M. Saracino, Giulia Fiorini, Frode Lerang, Sotirios Georgopoulos, Bojan Tepes, Frederic Heluwaert, Antonio Gasbarrini, Theodore Rokkas, Dmitry Bordin, Sinead Smith, Vincent Lamy, María Caldas, Elena Resina, Raquel Muñoz, Ángel Cosme, Ignasi Puig, Francis Megraud, Colm O’Morain, Javier P. Gisbert. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics 2021; 10(9): 1058 doi: 10.3390/antibiotics10091058
|
| 13 |
|
| 14 |
Vladimir Milivojević, Miodrag Krstić, Branislava Medić-Brkić. Influence of antibiotic resistance in the treatment of Helicobacter pylori infection. Medicinski podmladak 2023; 74(2): 7 doi: 10.5937/mp74-41665
|
| 15 |
Samuel Costa, João-Bruno Soares, Raquel Gonçalves. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1258 doi: 10.1097/MEG.0000000000000960
|
| 16 |
Enzo Ierardi, Giuseppe Losurdo, Rosa Federica La Fortezza, Mariabeatrice Principi, Michele Barone, Alfredo Di Leo. Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectiveness. World Journal of Gastroenterology 2019; 25(34): 5097-5104 doi: 10.3748/wjg.v25.i34.5097
|
| 17 |
Seokin Kang, Yuri Kim, Ji Yong Ahn, Hwoon-Yong Jung, Nayoung Kim, Hee Kyong Na, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics 2021; 10(2): 214 doi: 10.3390/antibiotics10020214
|
| 18 |
Yong Hwan Kwon, Nayoung Kim, Ju Yup Lee, Yoon Jin Choi, Kichul Yoon, Ryung Hee Nam, Ji Hyung Suh, Jung Won Lee, Dong Ho Lee. Comparison of the efficacy of culture-based tailored therapy forHelicobacter pylorieradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scandinavian Journal of Gastroenterology 2016; 51(3): 270 doi: 10.3109/00365521.2015.1095352
|
| 19 |
|
| 20 |
Mara Di Giulio, Emanuela Di Campli, Soraya Di Bartolomeo, Valentina Cataldi, Leonardo Marzio, Laurino Grossi, Antonio Francesco Ciccaglione, Antonia Nostro, Luigina Cellini. In vitroantimicrobial susceptibility ofHelicobacter pylorito nine antibiotics currently used in Central Italy. Scandinavian Journal of Gastroenterology 2016; 51(3): 263 doi: 10.3109/00365521.2015.1092577
|
| 21 |
John KC Yee. <i>Helicobacter pylori</i> colonization of the oral cavity: A milestone discovery. World Journal of Gastroenterology 2016; 22(2): 641-648 doi: 10.3748/wjg.v22.i2.641
|
| 22 |
Mohamed Metwally, Raghda Ragab, Hasnaa S Abdel Hamid, Nashwa Emara, Hany Elkholy. Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study. Infection and Drug Resistance 2022; : 5905 doi: 10.2147/IDR.S386082
|
| 23 |
Rocío Bonoso Criado, Laura Pérez Citores, Antonio Germán Pérez-Millán, Ángela Martina Montero Moretón, Elena González De Castro, Luis Cabezudo Molleda, María Antonia García Castro, Bruno Antonio Moreira Da Silva, Sergio Maestro Antolín, Fernando Santos Santamarta, Javier Barcenilla Laguna. PROSPECTIVE COMPARATIVE STUDY OF THE TREATMENT OF HELICOBACTER PYLORI WITH ANTIBIOTIC SUSCEPTIBILITY TESTING-GUIDED TRIPLE THERAPY COMPARED TO QUADRUPLE THERAPY WITH PYLERA�. Revista Española de Enfermedades Digestivas 2020; doi: 10.17235/reed.2020.7395/2020
|
| 24 |
Yunjie Li, Xiaoxiao Hu, Ding Ding, Yuxiu Zou, Yiting Xu, Xuewei Wang, Yin Zhang, Long Chen, Zhuo Chen, Weihong Tan. In situ targeted MRI detection of Helicobacter pylori with stable magnetic graphitic nanocapsules. Nature Communications 2017; 8(1) doi: 10.1038/ncomms15653
|
| 25 |
Olga P. Nyssen, Marta Espada, Javier P. Gisbert. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.913436
|
| 26 |
Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P Gisbert, Jyh-Ming Liou, Christian Schulz, Antonio Gasbarrini, Richard H Hunt, Marcis Leja, Colm O'Morain, Massimo Rugge, Sebastian Suerbaum, Herbert Tilg, Kentaro Sugano, Emad M El-Omar. Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report. Gut 2022; 71(9): 1724 doi: 10.1136/gutjnl-2022-327745
|
| 27 |
Javier P. Gisbert. Empirical or susceptibility-guided treatment forHelicobacter pyloriinfection? A comprehensive review. Therapeutic Advances in Gastroenterology 2020; 13: 175628482096873 doi: 10.1177/1756284820968736
|
| 28 |
|
| 29 |
|
| 30 |
Jae Ho Choi, Young Joo Yang, Chang Seok Bang, Jae Jun Lee, Gwang Ho Baik. Current Status of the Third-LineHelicobacter pyloriEradication. Gastroenterology Research and Practice 2018; 2018: 1 doi: 10.1155/2018/6523653
|
| 31 |
Ana Morilla Morilla, Marta E. Álvarez-Argüelles, Jose María Duque, Edisa Armesto, Henar Villar, Santiago Melón. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología (English Edition) 2019; 42(8): 476 doi: 10.1016/j.gastre.2019.05.003
|
| 32 |
Marcello Fiorani, Ege Tohumcu, Livio Enrico Del Vecchio, Serena Porcari, Giovanni Cammarota, Antonio Gasbarrini, Gianluca Ianiro. The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota. Antibiotics 2023; 12(4): 765 doi: 10.3390/antibiotics12040765
|
| 33 |
Giuseppe Losurdo, Andrea Iannone, Floriana Giorgio, Mariabeatrice Principi, Alfredo Di Leo, Enzo Ierardi. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen forHelicobacter pylorieradication: how should rifabutin be managed in rescue regimens?. United European Gastroenterology Journal 2016; 4(3): 474 doi: 10.1177/2050640615623697
|
| 34 |
J K C Yee. Are the view of Helicobacter pylori colonized in the oral cavity an illusion?. Experimental & Molecular Medicine 2017; 49(11): e397 doi: 10.1038/emm.2017.225
|